Literature DB >> 851390

Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy.

R Sockolov, B Irwin, R H Dressendorfer, E M Bernauer.   

Abstract

To determine effects of severe muscular dystrophy on the performance of dynamic exercise, cardiorespiratory responses to incremental work on a bicycle ergometer and isokinetic limb strength measurements were compared for 13 dystrophic boys and 13 normal, untrained boys. The dystrophic boys (D) were matched to the normal boys (N) on the basis of age (8.4 yr), height (125 cm) and weight (25.7 kg). At rest, the dystrophic group had higher heart rates (HR) (D = 102; D = 31; N = 39 ml), with no difference in oxygen uptake (VO2), calculated cardiac output (Q), pulmonary ventilation (VE), or respiratory exchange ratio (R). During submaximal work, VO2, SV, Q and VE were lower in D. During maximal work, D had lower peak values for work rate (D = 400; N = 600 kg/min), endurance (D = 41; N = 60 ml), Q (D = 5.2; N = 11.0 liters/min), VE (D = 8.2; N = 36.9 liters/min), and R (D = 0.84; N = 0.99). Arm and leg strengths (four flexion and four extension motions) were lower in D, but muscle girths were not necessarily smaller. The findings indicate exercise performance in D was below normal and limited by low cardiorespiratory capacities, diminished leg strength, and perhaps reduced peripheral oxygen utilization. Duchenne muscular dystrophy, even in its early stages, apparently affects the work capacity of cardiac and pulmonary muscles as well as limb muscles.

Entities:  

Mesh:

Year:  1977        PMID: 851390

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  9 in total

Review 1.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

2.  Altered ROS production, NF-κB activation and interleukin-6 gene expression induced by electrical stimulation in dystrophic mdx skeletal muscle cells.

Authors:  Carlos Henríquez-Olguín; Francisco Altamirano; Denisse Valladares; José R López; Paul D Allen; Enrique Jaimovich
Journal:  Biochim Biophys Acta       Date:  2015-04-07

Review 3.  Nutrition strategies to improve physical capabilities in Duchenne muscular dystrophy.

Authors:  J Davoodi; C D Markert; K A Voelker; S M Hutson; Robert W Grange
Journal:  Phys Med Rehabil Clin N Am       Date:  2011-12-13       Impact factor: 1.784

4.  Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy.

Authors:  M Sander; B Chavoshan; S A Harris; S T Iannaccone; J T Stull; G D Thomas; R G Victor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Non-invasive assessment of muscle injury in healthy and dystrophic animals with electrical impedance myography.

Authors:  Benjamin Sanchez; Shama R Iyer; Jia Li; Kush Kapur; Su Xu; Seward B Rutkove; Richard M Lovering
Journal:  Muscle Nerve       Date:  2017-03-24       Impact factor: 3.217

6.  Exercise stress testing in children with metabolic or neuromuscular disorders.

Authors:  Tim Takken; Wim G Groen; Erik H Hulzebos; Cornelia G Ernsting; Peter M van Hasselt; Berthil H Prinsen; Paul J Helders; Gepke Visser
Journal:  Int J Pediatr       Date:  2010-07-15

7.  The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.

Authors:  Eduard Gappmaier
Journal:  Cardiopulm Phys Ther J       Date:  2012-06

8.  Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients.

Authors:  Janek Hyzewicz; Urs T Ruegg; Shin'ichi Takeda
Journal:  J Neuromuscul Dis       Date:  2015-11-22

9.  Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice.

Authors:  Justin M Percival; Kendra N E Anderson; Paul Gregorevic; Jeffrey S Chamberlain; Stanley C Froehner
Journal:  PLoS One       Date:  2008-10-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.